Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Merck & Co, Inc.
Target Audience: The intended audience for this activity is medical oncologists, urologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with bladder cancer.
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Review the role of the immune checkpoint signaling in tumor biology and the rationale for use of immunotherapeutic agents that target these processes.
- Evaluate the latest efficacy and safety data of available and emerging immunotherapies for the treatment of advanced bladder cancer.
- Determine best practices for the incorporation of immune checkpoint inhibitors into existing treatment paradigms for patients with advanced bladder cancer.
Activity Chair:
Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology and Urology
Co-Director, Signal Transduction Research Program
Yale School of Medicine
New Haven, CT
Faculty:
David I. Quinn, MD, PhD, FRACP, FACP
Associate Professor of Medicine (Clinical Scholar)
Section Head, Genitourinary Oncology
Division of Cancer Medicine and Blood Diseases in The Department of Medicine
Keck School of Medicine
University of Southern California
Los Angeles, CA
Jonathan E. Rosenberg, MD
Deputy Chair
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Walter M. Stadler, MD, FACP
Fred C. Buffett Professor of Medicine and Surgery
Chief, Section of Hematology/Oncology
Director, Genitourinary Program
The University of Chicago Medicine
Chicago, IL
Reviewers:
Ronald A. Codario MD, FACP, FNLA, RPVI, CHCP
Leonard Gomella, MD
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 3, 2017 to April 2, 2018.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty members report the following relationships:
Daniel P. Petrylak, MD
Consulting Fee: Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millineum, Pfizer, Roche, Sanofi-Aventis, Tyme
Contracted Research: Agenysis, Celgene, Dendreon, Eli Lilly, Johnson & Johnson, Millineum, Oncogenix, Progenics, Roche, Sanofi-Aventis
Ownership Interest: Bellicum, Tyme
David I. Quinn, MD, PhD, FRACP, FACP
Consulting Fee: Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Dendreon, EMD Serono, Genentech, Medivation, Merck, Novartis, Peleton, Pfizer, Sanofi
Contracted Research: Pfizer, SFJ Pharmaceuticals
Jonathan E. Rosenberg, MD
Consulting Fee: Agensys, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, EMD Serono, Genentech/Roche, Merck, Sanofi US, Seattle Genetics
Contracted Research: Genentech/Roche, Novartis
Ownership Interest: Illumina, Merck
Walter M. Stadler, MD, FACP
Consulting Fee: AstraZeneca, Pfizer, Roche
Contracted Research: AstraZeneca, Bristol-Myers-Squibb, Caremark-CVS, Merck, Novartis, Pfizer, Roche
Reviewers report the following relationship(s):
Ronald A. Codario MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Leonard Gomella, MD
Consulting Fee: Astellas, Bayer, Janssen, MDxHealth, Merck
Intellectual Property/Patent: Patent applied for a cancer urine test but not awarded yet.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2017 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com